PortfoliosLab logoPortfoliosLab logo
VRNA vs. SMMT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VRNA vs. SMMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Summit Therapeutics Inc. (SMMT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


VRNA

1D
1M
6M
YTD
1Y
3Y*
5Y*
10Y*
ALL TIME*

SMMT

1D
-8.81%
1M
-4.14%
6M
-17.16%
YTD
-21.90%
1Y
-50.45%
3Y*
89.42%
5Y*
11.29%
10Y*
6.69%
ALL TIME*
2.76%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$54.17M$58.39M$81.75M

VRNA vs. SMMT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%21.74%-40.41%-18.71%-12.07%
SMMT
Summit Therapeutics Inc.
-21.90%-1.99%583.72%-38.59%57.99%-42.77%193.75%39.13%-89.62%1.93%

Correlation

The correlation between VRNA and SMMT is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Apr 27, 2017

0.10

Fundamentals

Market Cap

VRNA:

$9.72B

SMMT:

$10.60B

EPS

VRNA:

-$0.69

SMMT:

-$1.12

PB Ratio

VRNA:

34.92

SMMT:

16.87

Total Revenue (TTM)

VRNA:

$167.65M

SMMT:

$0.00

Gross Profit (TTM)

VRNA:

$159.52M

SMMT:

$0.00

EBITDA (TTM)

VRNA:

-$40.86M

SMMT:

-$640.21M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VRNA vs. SMMT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


SMMT
SMMT Risk / Return Rank: 1515
Overall Rank
SMMT Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
SMMT Sortino Ratio Rank: 1919
Sortino Ratio Rank
SMMT Omega Ratio Rank: 1818
Omega Ratio Rank
SMMT Calmar Ratio Rank: 88
Calmar Ratio Rank
SMMT Martin Ratio Rank: 1313
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. SMMT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VRNASMMTDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

0.90

Calmar ratioReturn relative to maximum drawdown

-0.91

Martin ratioReturn relative to average drawdown

-1.30

VRNA vs. SMMT - Sharpe Ratio Comparison


Loading charts...

Drawdowns

VRNA vs. SMMT - Drawdown Comparison


Loading charts...

Drawdown Indicators


VRNASMMTDifference

Max Drawdown

Largest peak-to-trough decline

-95.75%

Max Drawdown (1Y)

Largest decline over 1 year

-55.49%

Max Drawdown (3Y)

Largest decline over 3 years

-64.44%

Max Drawdown (5Y)

Largest decline over 5 years

-91.78%

Max Drawdown (10Y)

Largest decline over 10 years

-95.75%

Current Drawdown

Current decline from peak

-62.78%

Average Drawdown

Average peak-to-trough decline

-57.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

38.73%

Volatility

VRNA vs. SMMT - Volatility Comparison


Loading charts...

Volatility by Period


VRNASMMTDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.45%

Volatility (6M)

Calculated over the trailing 6-month period

56.03%

Volatility (1Y)

Calculated over the trailing 1-year period

73.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

185.18%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

144.54%

Dividends

VRNA vs. SMMT - Dividend Comparison

Neither VRNA nor SMMT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VRNA vs. SMMT - Financials Comparison

This section allows you to compare key financial metrics between Verona Pharma plc and Summit Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M20222023202420252026
75.14M
0
(VRNA) Total Revenue
(SMMT) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VRNA and SMMT have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for VRNA and SMMT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer